Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Judy Lieberman
Boston Children's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
SMOC Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Lieberman has a financial interest in and co-founded SMOC Therapeutics (“SMOC” or “Company”), a Company that intends to develop a platform for drug discovery in the area of inflammation. The subject grant involves GSDM proteins. The research has previously been unrelated to the Company. Although Dr. Lieberman’s work is distinct form the work of the Company in that Dr. Lieberman studies the functions of these proteins, while the company is pursuing therapeutics for various diseases, the outcome of Dr. Lieberman’s research may have the potential to indirectly benefit the company. In addition, Dr. Lieberman also proposed to screen for small molecule inhibitors in her lab independently of the company. However if proprietary small molecule inhibitors are identified in her lab, it is possible that SMOC Therapeutics (or other companies) may be interested in licensing them.
Elucidating the structural mechanism of pore formation by the (GSDM) Gasdermin family
GSDMs are associated with many human diseases, and deletion of GSDMD significantly decreases pyroptosis and IL-1? secretion, and remarkably protects mice from sepsis. Genetic mutations in GSDMA3, GSDME or DFNB59 cause alopecia and hyperkeratosis in mice and nonsyndromic hearing loss in humans, while polymorphism of GSDMB is linked to increased asthma and IBD risk. Elucidating the structural mechanism of pore formation by GSDMs will have significant impact on generating potential therapeutics against these diseases.
Filed on June 10, 2019.
Tell us what you know about Judy Lieberman's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Judy Lieberman”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Judy Lieberman | Boston Children's Hospital | Conflict of Interest | SMOC Therapeutics | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.